U.S. flag

An official website of the United States government

NC_000005.9:g.(?_175158654)_(179263593_?)dup AND Sotos syndrome

Germline classification:
no classifications from unflagged records (1 submission)
Review status:
no classifications from unflagged records
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003232857.10

Allele description [Variation Report for NC_000005.9:g.(?_175158654)_(179263593_?)dup]

NC_000005.9:g.(?_175158654)_(179263593_?)dup

Genes:
Variant type:
Duplication
Cytogenetic location:
5q35.2-35.3
Genomic location:
Chr5: 175158654 - 179263593 (on Assembly GRCh37)
Preferred name:
NC_000005.9:g.(?_175158654)_(179263593_?)dup
HGVS:
NC_000005.9:g.(?_175158654)_(179263593_?)dup

Condition(s)

Name:
Sotos syndrome (SOTOS)
Synonyms:
Sotos' syndrome; Cerebral gigantism; Distinctive facial appearance, overgrowth in childhood, and learning disabilities or delayed development; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0019349; MedGen: C0175695; Orphanet: 821; OMIM: 117550

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

No clinical assertions found. See "Flagged submissions" below.

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Molecular cytogenetic analysis of de novo dup(5)(q35.2q35.3) and review of the literature of pure partial trisomy 5q.

Chen CP, Lin SP, Lin CC, Chen YJ, Chern SR, Li YC, Hsieh LJ, Lee CC, Pan CW, Wang W.

Am J Med Genet A. 2006 Jul 15;140(14):1594-600. Review.

PubMed [citation]
PMID:
16770806
See all PubMed Citations (9)

Details of each submission

From Invitae, SCV003791914.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (9)

Description

A copy number gain of the genomic region encompassing the full coding sequence of the NSD1 gene has been identified. The boundaries of this event are unknown as they extend beyond the assayed region for this gene and therefore may encompass additional genes. As the precise location of this event is unknown, it may be in tandem or it may be located elsewhere in the genome. Isolated whole-gene copy number gains of NSD1 have not been reported in the literature. However, larger copy number events that include this gene have been reported (PMID: 16770806, 17090394, 21567906, 23599694, 23913520, 24819041, 28128410, 33389145). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that a similar copy number variant affects NSD1 function (PMID: 33389145). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Flagged submissions

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003791914Invitae
flagged submission
Reason: This record appears to be redundant with a more recent record from the same submitter.
Notes: SCV003791914 appears to be redundant with SCV003843969.

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jul 25, 2022)
germlineclinical testing

PubMed (9)
[See all records that cite these PMIDs]

Last Updated: May 26, 2024